"OncoLens' focus on not just delivering insights but usability tools such as provider targeted alerts, continues to excite us along with their already impressive growth." Mark Buffington, @bipventures
We're thrilled to be part of the B group..the Series B group.
We count our lucky stars by the number of cancer patient lives we can touch and we look forward to achieving even more major milestones alongside our wonderful customers.
Link: https://t.co/dby7fZ4hJs
Looking forward to discussing the latest data on Functional Precision Medicine Assays for high grade glioma. Tune in February 12 at noon EST. @KIYATEC@OncoLens Register below: https://t.co/grapirWJdA
It's Friday ‘Fund’ Day! We have funding news from GA-based oncology health tech startup @OncoLens, North Carolina-based audio tech company, @BrainTapTech, and more: https://t.co/I4JFFzCgfJ
Join us at the @ACCCBuzz Annual NOC Conference
Stop by Booth 623 and learn how The OncoLens Research Network offers relevant, highly curated industry-sponsored initiatives, like clinical trials and disease-specific QIP’s, including innovative programs targeted to improve biomarker testing compliance to guidelines.
We look forward to seeing you this week!
We are excited to announce OncoLens' recognition by @inc5000 as one of the Fastest-Growing Private Companies in America, for the second year in a row!
https://t.co/eJg6z9yZpY
It's critical to wait for biomarker results before starting treatment for lung cancer - how do we balance that with the urgency to start treatment quickly? Advice from patient advocate Aurora Lucas & Drs. Mark Kris & @TurgemanIlit in this @IASLC podcast.
https://t.co/lK3UbP2ylc
New Study on the Benefits of Cancer Survivorship Care
@TimMullettMD, thoracic surgeon at @UKMarkey and chair of the @AmColSurgCancer (#ACS) Commission on Cancer (#CoC), co-authored a groundbreaking study on the value of cancer survivorship care standards. This research underscores the importance of structured care programs for cancer survivors, aiming to enhance their quality of life and long-term health outcomes.
The study highlights:
- Improved patient outcomes with standardized care
- The need for comprehensive follow-up plans
- Strategies for integrating survivorship care into clinical practice and multidisciplinary collaboration
Read more about this significant advancement in cancer care:
Markey physician co-authors study on value of cancer survivorship care standards:
https://t.co/nBwrkewvJH
and the full study here - JAMA Network Open:
https://t.co/J8KdmqEYDt
#SurvivorshipCare #MultidisciplinaryCancerCare #HealthcareInnovation #MedicalResearch
.@TimMullettMD@UKMarkey explores research on cancer survivors. With the number of adult cancer survivors in the U.S. expected to reach 23 million by 2032, the long-term needs of this population are growing, yet often poorly understood and addressed.
https://t.co/9CBp9HIK9e
There is still time to register for the final session of the Project ECHO tele-mentoring series on bispecific antibodies and care coordination. Earn 1.0 CME, CPE, or CNE credit when you complete the session. Register now at https://t.co/D8eFBHVLKP.
Powered by @OncoLens
.@UKMarkey Medical oncologist Ralph Zinner, MD presents on a clinical trial targeting stage IIIA-C non-small cell #lungcancer (NSCLC) at #ACSO24@ACSO@ResearchKY
https://t.co/84HDPf6h62
#ASCO24#LAURA I’m putting this 👏standing ovation video out here for all the patients and investigators who participated in this practice changing study.
➡️ But, let’s all remember that we can’t celebrate until all patients get #biomarkertesting and access to these life-saving drugs in a more cost-effective way #GlobalOnc #lcsm @EGFRResisters@YoungLungCancer